Abstract
Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine D2 receptors, as well as a potent antagonist of 5-HT2A receptors and noradrenergic α1B and α2C receptors. In July 2015, brexpiprazole received its first approval in the USA for use as an adjunctive treatment of major depressive disorder (MDD) and the treatment of schizophrenia. In several countries, brexpiprazole is in development for MDDs, schizophrenia, post-traumatic stress disorder and agitation in patients with dementia of the Alzheimer’s type. This article summarizes the milestones in the development of brexpiprazole leading to its first global approval in MDD and schizophrenia.
Similar content being viewed by others
References
Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.
Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014;351(3):585–95.
Otsuka Pharmaceutical Co. Ltd. Rexulti® (brexpiprazole) tablets for oral use: US prescribing information. 2015. http://www.otsuka-us.com. Accessed 6 Aug 2015.
US Food and Drug Administration. FDA approves new drug to treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder [media release]. 13 July 2015. http://www.fda.gov.
Otsuka Pharmaceutical Co. Ltd. US FDA approves Otsuka and Lundbeck’s Rexulti® (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia [media release]. 10 July 2015. http://www.otsuka.co.jp.
Otsuka Pharmaceutical Co. Ltd, H. Lundbeck A/S. Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S sign historic agreement to deliver innovative medicines with focus on psychiatric disorders worldwide [media release]. 10 Nov 2011. http://www.otsuka.co.jp.
H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd. Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide [media release]. 11 Nov 2011. http://www.lundbeck.com.
Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–14.
Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25(3):356–64.
Wong DF, Malikaarjun S, Raofinia A, et al. A phase I, open-label PET study of the pharmacokinetics, tolerability and D2/D3 striatal occupancy of single-dose oral OPC-34712 in healthy subjects [abstract no. 619]. Biol Psychiatry. 2011;69(9 Suppl 1):S187.
Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015. doi:10.4088/JCP.14m09688.
Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015. doi:10.4088/JCP.14m09689.
Eriksson H, Weiller E, Weiss C, et al. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: meta-analysis of two pivotal studies [abstract no. 42]. In: American Psychiatric Association Annual Meeting. 2015.
Thase M, Fava M, Hobart M, et al. Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: a phase II, randomized, placebo-controlled study [abstract no. 193]. Neuropsychopharmacology. 2011;36:S302–4.
Menard F, Fava M, Davidsen CK, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and irritability: an exploratory study [abstract no. 174]. Biol Psychiatry. 2015;77(9 Supplement 1):S65.
Davis LL, Ota A, Perry P, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study [abstract no. 177]. Biol Psychiatry. 2015;77(9 Supplement 1):S66.
Krystal A, Mittoux A, Meisels P, et al. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and sleep disturbances: an exploratory study [abstract no. 173]. Biol Psychiatry. 2015;77(9 Supplement 1):S64–5.
Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–35.
Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015. doi:10.1176/appi.ajp.2015.14101275.
Skuban A, Correll CU, Kane JM, et al. Efficacy of brexpiprazole (OPC-34712) in acute schizophrenia: results of two pooled pivotal studies [abstract no. 2089994]. Schizophr Bull. 2015;41:S333–4.
McQuade R, Hobart M, Forbes RA, et al. A phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (study 331-07-203) [abstract no. 140]. In: US Psychiatric and Mental Health Congress. 2011.
Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study [abstract no. 560]. Biol Psychiatry. 2015;77(9 Supplement 1):S203.
Weiller E, Skuban A, Weiss C, et al. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies [abstract no. 57]. In: American Psychiatric Association Annual Meeting. 2015.
Correll CU, Skuban A, Ouyang J, et al. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies [abstract no. 2089877]. Schizophr Bull. 2015;41:S307.
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sarah Greig is a salaried employee of Adis, Springer SBM.
Author information
Authors and Affiliations
Corresponding author
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Greig, S.L. Brexpiprazole: First Global Approval. Drugs 75, 1687–1697 (2015). https://doi.org/10.1007/s40265-015-0462-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-015-0462-2